Kummer Marvin, El-Battrawy Ibrahim, Gietzen Thorsten, Ansari Uzair, Behnes Michael, Lang Siegfried, Zhou Xiaobo, Borggrefe Martin, Akin Ibrahim
First Department of Medicine, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site, Heidelberg-Mannheim, Mannheim, Germany.
Front Pharmacol. 2020 May 14;11:681. doi: 10.3389/fphar.2020.00681. eCollection 2020.
Takotsubo syndrome (TTS) and acute coronary syndrome (ACS) patients have a similar mortality rate. In this study, we sought to determine the short- and long-term outcome of TTS patients as compared to ACS patients both treated with beta-blockers.
In the present study we described the data of 5 years of follow up of 103 TTS and 422 ACS patients both treated with beta-blockers.
Data from TTS patients were included retrospectively and prospectively, ACS patients were included retrospectively. All retrospectively included patients have been followed up for 5 years. The end point in this study was the occurrence of death.
TTS affected significantly more women (87.4%) than ACS (34.6%) (p < 0.01). TTS patients suffered significantly more often from thromboembolic events (14.6% versus 2.1%; p < 0.01) and cardiogenic shock (11.9% versus 3.6%; p < 0.01) than the ACS group. TTS patients had a significantly higher long-term mortality (within 5 years) as compared to ACS patients (17.5% versus 3.6%) (p < 0.01). Patients of the TTS group compared to the ACS group did not benefit from combination of beta-blockers and ACE-inhibitors in terms of long-term mortality (p < 0.01). As we compare TTS patients who were treated with beta-blockers and ACE-inhibitors versus single use of beta-blockers there was no difference in long-term mortality (p = 0.918).
TTS patients had a significantly higher long-term mortality (within 5 years) than patients with an ACS.
应激性心肌病（TTS）患者与急性冠状动脉综合征（ACS）患者的死亡率相似。在本研究中，我们试图确定与接受β受体阻滞剂治疗的ACS患者相比，TTS患者的短期和长期预后。
在本研究中，我们描述了103例接受β受体阻滞剂治疗的TTS患者和422例接受β受体阻滞剂治疗的ACS患者5年的随访数据。
回顾性和前瞻性纳入TTS患者的数据，回顾性纳入ACS患者的数据。所有回顾性纳入的患者均随访5年。本研究的终点是死亡的发生。
TTS患者中女性（87.4%）明显多于ACS患者（34.6%）（p<0.01）。与ACS组相比，TTS患者发生血栓栓塞事件（14.6%对2.1%；p<0.01）和心源性休克（11.9%对3.6%；p<0.01）的频率明显更高。与ACS患者相比，TTS患者的长期死亡率（5年内）明显更高（17.5%对3.6%）（p<0.01）。在长期死亡率方面，TTS组患者与ACS组患者相比，未从β受体阻滞剂和血管紧张素转换酶抑制剂联合使用中获益（p<0.01）。当我们比较接受β受体阻滞剂和血管紧张素转换酶抑制剂治疗的TTS患者与单用β受体阻滞剂的患者时，长期死亡率没有差异（p=0.918）。
TTS患者的长期死亡率（5年内）明显高于ACS患者。
